KETA.CN TripSitter Clinic Ltd. CNQ up 226% on 06 Feb 2026: model warns

KETA.CN stock surged 226.67% to C$0.49 on 06 Feb 2026 during market hours, driven by a sharp single-day price move from the previous close of C$0.15. The jump pushed the year high to C$0.49 and left average trading metrics unchanged: average volume 1,134 and market cap about C$3,262,505.00. Traders should note the one-day increase occurred on zero reported volume in the feed, which raises questions about liquidity and trade reporting. We cover drivers, financials, technicals, and a model forecast that highlights risk

KETA.CN stock: price action and session details

The main fact is the intraday move: TripSitter Clinic Ltd. (KETA.CN) opened and traded at C$0.49, changing +C$0.34 or +226.67% from the previous close of C$0.15. The dataset records day low and day high both at C$0.49 and year low at C$0.03. Shares outstanding are 6,658,174 and reported market cap is C$3,262,505.00, showing this is a micro-cap with high nominal volatility.

One clear risk from the trading data is liquidity: reported volume for the session is 0, while average volume is 1,134, indicating possible irregular trade reporting or off-exchange prints. For active traders, a zero-volume print at a new year high signals caution on execution and price reliability.

What likely drove the move and KETA.CN news context

The company operates a tele-health ketamine treatment platform serving multiple U.S. states and is listed on CNQ in Canada. There is no official earnings or corporate press release in the feed tied to this move. The sudden spike without accompanying public filings suggests speculative buying, a thin-order book, or delayed reporting of small block trades.

Investors should cross-check filings and news wires and review the company website for updates source. For raw profile and historical metrics consult a market data provider source.

KETA.CN stock: financials and valuation snapshot

TripSitter Clinic reports EPS of -0.04 and a listed PE of -12.25, reflecting negative earnings and a small base. Key ratios show cash-per-share C$0.00 (rounded 0.00), book value per share -0.12, and price averages 50-day C$0.06 and 200-day C$0.07. The company has enterprise value near C$3,651,013.00 and operating cash flow per share -0.01.

Compared with the Healthcare sector average P/E of about 14.24, KETA.CN stock is deeply unprofitable and materially out of line on valuation metrics. That gap frames much of the downside risk for longer-term investors.

Technicals, volume and trading metrics

Technical indicators are noisy due to thin trading. Reported RSI is 0.00, ADX is 100.00 (strong trend) and Bollinger middle band is C$0.06. On moving averages the stock trades well above the 50-day C$0.0588 and 200-day C$0.0658 averages. On-chain metrics record On Balance Volume -5,500.00, reflecting prior net outflows.

Because average daily volume is only 1,134 shares, a few trades can move price drastically. Traders should expect large bid-ask spreads and use limit orders if they enter positions.

Meyka AI rates and KETA.CN forecast

Meyka AI rates KETA.CN with a score out of 100: 63.35 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors.

Meyka AI’s forecast model projects a monthly target of C$0.08 and a quarterly target of C$0.06 versus the current price C$0.49, implying a model-based downside of -83.67% to the monthly forecast and -87.76% to the quarterly forecast. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context

Primary risks include negligible liquidity, negative earnings, weak balance-sheet metrics (book value per share -0.12), and limited public disclosures. Regulatory or clinical news could be a catalyst, given the company’s tele-health ketamine focus in the Healthcare sector.

Sector performance is mixed; Healthcare peers show better scale and positive revenue profiles. For speculative investors, any material news, a larger trade block, or formal corporate update could reprice the stock quickly. For conservative investors, the valuation and low liquidity recommend caution.

Final Thoughts

KETA.CN stock posted a one-day rise of 226.67% to C$0.49 on 06 Feb 2026, but the move lacks clear supporting volume or public announcements. The company is a micro-cap listed on CNQ in Canada, with 6,658,174 shares outstanding, EPS -0.04, and a market cap near C$3,262,505.00. Our quantitative grade places the stock at 63.35 (Grade B, HOLD) after weighing benchmarks, sector metrics, and financial growth. Meyka AI’s forecast model shows a monthly target of C$0.08, implying -83.67% downside from the current price; the quarterly target is C$0.06. These forecasts reflect mean-reversion to historical average prices and thin liquidity rather than fundamental improvement. Short-term traders can profit from volatility but must use strict risk controls and limit orders. Long-term investors should wait for verified company news, stronger revenue signals, and improved liquidity before adding KETA.CN to a portfolio. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.